Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNotes PayablesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Jin Medical International (ZJYL) Finished Goods (2022 - 2025)

Jin Medical International (ZJYL) has disclosed Finished Goods for 4 consecutive years, with $915839.0 as the latest value for Q3 2025.

  • Quarterly Finished Goods fell 33.02% to $915839.0 in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $915839.0 through Sep 2025, down 33.02% year-over-year, with the annual reading at $915839.0 for FY2025, 33.02% down from the prior year.
  • Finished Goods hit $915839.0 in Q3 2025 for Jin Medical International, down from $1.4 million in the prior quarter.
  • In the past five years, Finished Goods ranged from a high of $2.1 million in Q3 2022 to a low of $820949.0 in Q3 2023.
  • Historically, Finished Goods has averaged $1.3 million across 4 years, with a median of $1.1 million in 2024.
  • Biggest five-year swings in Finished Goods: tumbled 59.97% in 2023 and later surged 66.57% in 2024.
  • Year by year, Finished Goods stood at $2.1 million in 2022, then tumbled by 59.97% to $820949.0 in 2023, then soared by 66.57% to $1.4 million in 2024, then tumbled by 33.02% to $915839.0 in 2025.
  • Business Quant data shows Finished Goods for ZJYL at $915839.0 in Q3 2025, $1.4 million in Q3 2024, and $820949.0 in Q3 2023.